|
1
|
Glaser AM, Johnston JH, Gleason WA and
Rhoads JM: Myotonic dystrophy as a cause of
colonicpseudoobstruction: Not just another constipated child. Clin
Case Rep. 3:424–426. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Finsterer J, Karpatova A, Rauschka H,
Loewe-Grgurin M, Frank M and Gencik M: Myotonic dystrophy 2
manifesting with non-alcoholic and non-hepatitic liver cirrhosis.
Acta Clin Belg. 70:432–435. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Omond KJ and Byard RW: Forensic
considerations in cases of myotonic dystrophy at autopsy. J
Forensic Sci. Feb 7–2017.(Epub ahead of print). View Article : Google Scholar
|
|
4
|
Tschuppert S and Gerding H: Myotonic
dystrophy with reticular maculopathy as first ocular symptom. Klin
Monbl Augenheilkd. 232:568–569. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Finsterer J and Rudnik-Schöneborn S:
Myotonic dystrophies: Clinical presentation, pathogenesis,
diagnostics and therapy. Fortschr Neurol Psychiatr. 83:9–17.
2015.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thornton CA: Myotonic dystrophy. Neurol
Clin. 32705–719. (viii)2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mathieu J, Allard P, Potvin L, Prévost C
and Bégin P: A 10-year study of mortality in a cohort of patients
with myotonic dystrophy. Neurology. 52:1658–1662. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Smith CA and Gutmann L: Myotonic dystrophy
type 1 management and therapeutics. Curr Treat Options Neurol.
18:522016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Arandel L, Espinoza M Polay, Matloka M,
Bazinet A, De Dea Diniz D, Naouar N, Rau F, Jollet A, Edom-Vovard
F, Mamchaoui K, et al: Immortalized human myotonic dystrophy muscle
cell lines to assess therapeutic compounds. Dis Model Mech.
10:487–497. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Joyce NC, Oskarsson B and Jin LW: Muscle
biopsy evaluation in neuromuscular disorders. Phys Med Rehabil Clin
N Am. 23:609–631. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang SH, Zhu L, Wu ZH, Zhang Y, Tang GQ,
Jiang YZ, Li MZ, Bai L and Li XW: Effect of muscle-fiber type on
glycogenin-1 gene expression and its relationship with the
glycolytic potential and pH of pork. Genet Mol Res. 12:3383–3390.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kamsteeg EJ, Kress W, Catalli C, Hertz JM,
Witsch-Baumgartner M, Buckley MF, van Engelen BG, Schwartz M and
Scheffer H: Best practice guidelines and recommendations on the
molecular diagnosis of myotonic dystrophy types 1 and 2. Eur J Hum
Gene. 20:1203–1208. 2012. View Article : Google Scholar
|
|
13
|
Wissocque L, Brigadeau F, Richardson M,
Boulé S, Kouakam C, Polge AS, Marquié C and Klug D: Impairment of
global and regional longitudinal strains in patients with myotonic
dystrophy type 1. Int J Cardiol. 191:46–47. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gallais B, Montreuil M, Gargiulo M, Eymard
B, Gagnon C and Laberge L: Prevalence and correlates of apathy in
myotonic dystrophy type 1. BMC Neurol. 15:1482015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gladman JT, Mandal M, Srinivasan V and
Mahadevan MS: Age of onset of RNA toxicity influences phenotypic
severity: Evidence from an inducible mouse model of myotonic
dystrophy (DM1). PLoS One. 8:e729072013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Santoro M, Masciullo M, Silvestri G,
Novelli G and Botta A: Myotonic dystrophy type 1: Role of CCG CTC
and CGG interruptions within DMPK alleles in the pathogenesis and
molecular diagnosis. Clin Genet. Dec 19–2016.(Epub ahead of
print).
|
|
17
|
Lee JE, Bennett CF and Cooper TA: RNase
H-mediated degradation of toxic RNA in myotonic dystrophy type 1.
Proc Natl Acad Sci USA. 109:pp. 4221–4226. 2012; View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Meola G and Cardani R: Myotonic
dystrophies: An update on clinical aspects, genetic, pathology, and
molecular pathomechanisms. Biochim Biophys Acta. 1852:594–606.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
De Antonio M, Dogan C, Hamroun D, Mati M,
Zerrouki S, Eymard B, Katsahian S and Bassez G: French Myotonic
Dystrophy Clinical Network: Unravelling the myotonic dystrophy type
1 clinical spectrum: A systematic registry-based study with
implications for disease classification. Rev Neurol (Paris).
172:572–580. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gagnon C, Kierkegaard M, Blackburn C,
Chrestian N, Lavoie M, Bouchard MF and Mathieu J: Participation
restriction in childhood phenotype of myotonic dystrophy type 1: A
systematic retrospective chart review. Dev Med Child Neurol.
59:291–296. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Udd B and Krahe R: The myotonic
dystrophies: Molecular, clinical, and therapeutic challenges.
Lancet Neurol. 11:891–905. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Turner C and Hilton-Jones D: Myotonic
dystrophy: Diagnosis, management and new therapies. Curr Opin
Neurol. 27:599–606. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Groh WJ, Groh MR, Saha C, Kincaid JC,
Simmons Z, Ciafaloni E, Pourmand R, Otten RF, Bhakta D, Nair GV, et
al: Electrocardiographic abnormalities and sudden death in myotonic
dystrophy type 1. N Engl J Med. 358:2688–2697. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Meola G and Sansone V: Cerebral
involvement in myotonic dystrophies. Muscle Nerve. 36:294–306.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kornblum C, Reul J, Kress W, Grothe C,
Amanatidis N, Klockgether T and Schröder R: Cranial magnetic
resonance imaging in genetically proven myotonic dystrophy type 1
and 2. J Neurol. 251:710–714. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu L, Liu HM, Liu ZJ, Zhang LW, Gu WH and
Wang RB: Myotonic dystrophy type 1 associated with white matter
hyperintense lesions: Clinic, imaging, and genetic analysis. Chin
Med J (Engl). 128:1412–1414. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Minnerop M, Weber B, Schoene-Bake JC,
Roeske S, Mirbach S, Anspach C, Schneider-Gold C, Betz RC,
Helmstaedter C, Tittgemeyer M, et al: The brain in myotonic
dystrophy 1 and 2: Evidence for a predominant white matter disease.
Brain. 134:3530–3546. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Portaro S, Altamura C, Licata N, Camerino
GM, Imbrici P, Musumeci O, Rodolico C, Camerino D Conte, Toscano A
and Desaphy JF: Clinical, Molecular, and functional
characterization of CLCN1 mutations in three families with
recessive myotonia congenita. Neuromolecular Med. 17:285–296. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lakraj AA, Miller G, Vortmeyer AO, Khokhar
B, Nowak RJ and DiCapua DB: Novel mutations in the CLCN1 gene of
myotonia congenita: 2 case reports. Yale J Biol Med. 86:101–106.
2013.PubMed/NCBI
|
|
30
|
Kurihara T: New classification and
treatment for myotonic disorders. Intern Med. 44:1027–1032. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sechi GP, Traccis S, Durelli L, Monaco F
and Mutani R: Carbamazepine versus diphenylhydantoin in the
treatment of myotonia. Eur Neurol. 22:113–118. 1983. View Article : Google Scholar : PubMed/NCBI
|
